Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of VA combined with HAAG in the induction treatment of newly diagnosed acute myeloid leukemia.


Clinical Trial Description

This is a single-center, single-arm, prospective clinical study in newly diagnosed intermediate and high-risk AML patients. The patients will receive venetoclax, azacitidine combined with HAAG regimen in the induction treatment. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06394011
Study type Interventional
Source The First Affiliated Hospital of Soochow University
Contact Xiaowen Tang, Ph.D
Phone (0086)51267780086
Email xwtang1020@163.com
Status Recruiting
Phase Phase 2
Start date February 15, 2024
Completion date December 30, 2026

See also
  Status Clinical Trial Phase
Recruiting NCT05066958 - Ex-vivo Primed Memory Donor Lymphocyte Infusion to Boost Anti-viral Immunity After T-cell Depleted HSCT Phase 1/Phase 2
Recruiting NCT05237258 - Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia N/A
Completed NCT01696084 - Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia Phase 3
Active, not recruiting NCT02861417 - Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant Phase 2
Recruiting NCT03384212 - CBA Versus FBA Conditioning Followed by Allogeneic HSCT in Treatment of High Risk and Refractory AML Phase 3
Recruiting NCT03384225 - CBA Versus FBA Conditioning Followed by Haploidentical Allogeneic HSCT in Treatment of High Risk and Refractory AML Phase 3